Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference

Rhea-AI Summary

Q32 Bio (Nasdaq: QTTB), a clinical stage biotech company developing therapies for alopecia areata and other autoimmune and inflammatory diseases, will participate in the 2025 Wells Fargo Healthcare Conference. The company's management will engage in a fireside chat on September 4th at 3:45 p.m. E.T.

Investors can access the presentation through a webcast on Q32 Bio's website, with replays available for 90 days after the event.

WALTHAM, Mass., Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will participate in a fireside chat at 3:45 p.m. E.T. on Thursday, September 4^th at the 2025 Wells Fargo Healthcare Conference.

A webcast of the presentation will be available on the Events and Presentations page of Q32 Bio's website at www.q32bio.com. Archived replays will be available for 90 days following the event.

About Q32 Bio

Q32 Bio is a clinical stage biotechnology company whose science targets potent regulators of the adaptive immune system to re-balance immunity and is focused on developing innovative therapies for alopecia areata and other autoimmune and inflammatory diseases. About 700,000 people in the United States live with alopecia areata¹, a disease which has a life-altering impact on patients and limited current treatment options. Q32 Bio is advancing bempikibart (ADX-914), a fully human anti-IL-7Rα antibody that re-regulates adaptive immune function, for the treatment of alopecia areata in an ongoing Phase 2 program. The IL-7 and TSLP pathways have been genetically and biologically implicated in driving several T cell-mediated pathological processes in numerous autoimmune diseases.

For more information, visit www.Q32Bio.com.

¹National Alopecia Areata Foundation.

Availability of Other Information About Q32 Bio

Investors and others should note that Q32 Bio communicates with its investors and the public using its website www.Q32Bio.com, including, but not limited to, Q32 Bio's disclosures, investor presentations and FAQs, Securities and Exchange Commission (the "SEC") filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly Twitter) and LinkedIn. The information that Q32 Bio posts on its website or on X or LinkedIn could be deemed to be material information. As a result, Q32 Bio encourages investors, the media and others interested to review the information that it posts there on a regular basis. The contents of Q32 Bio's website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

Contacts:

Investors: Brendan Burns
Argot Partners
212.600.1902
Q32Bio@argotpartners.com

Media: David Rosen
Argot Partners
646.461.6387
david.rosen@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/q32-bio-to-participate-in-the-2025-wells-fargo-healthcare-conference-302540421.html

SOURCE Q32 Bio

FAQ

When is Q32 Bio (QTTB) presenting at the Wells Fargo Healthcare Conference 2025?

Q32 Bio will present in a fireside chat on Thursday, September 4th, 2025 at 3:45 p.m. E.T.

How can investors access Q32 Bio's Wells Fargo Conference presentation?

Investors can access the webcast through the Events and Presentations page on Q32 Bio's website (www.q32bio.com). The replay will be available for 90 days after the event.

What therapeutic areas does Q32 Bio (QTTB) focus on?

Q32 Bio focuses on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases.

What type of company is Q32 Bio (QTTB)?

Q32 Bio is a clinical stage biotechnology company listed on the Nasdaq under the symbol QTTB.